Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $150.5 million.

  • CorMedix's Cash from Financing Activities rose 96954.59% to $150.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $251.2 million, marking a year-over-year increase of 102957.24%. This contributed to the annual value of $26.3 million for FY2024, which is 5293.26% down from last year.
  • As of Q3 2025, CorMedix's Cash from Financing Activities stood at $150.5 million, which was up 96954.59% from $83.2 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Cash from Financing Activities ranged from a high of $150.5 million in Q3 2025 and a low of -$97118.0 during Q1 2024
  • Over the past 5 years, CorMedix's median Cash from Financing Activities value was $6.6 million (recorded in 2023), while the average stood at $23.8 million.
  • In the last 5 years, CorMedix's Cash from Financing Activities crashed by 10134.88% in 2024 and then surged by 777841.95% in 2025.
  • Over the past 5 years, CorMedix's Cash from Financing Activities (Quarter) stood at $176992.0 in 2021, then surged by 3315.74% to $6.0 million in 2022, then grew by 19.1% to $7.2 million in 2023, then surged by 56.73% to $11.3 million in 2024, then skyrocketed by 1233.92% to $150.5 million in 2025.
  • Its Cash from Financing Activities was $150.5 million in Q3 2025, compared to $83.2 million in Q2 2025 and $6.1 million in Q1 2025.